Cigna covers histrelin acetate (Supprelin LA) subcutaneous implant as medically necessary for suppression of puberty in adolescents with gender dysphoria when ALL of the following criteria are met:

- Documented diagnosis of gender dysphoria or gender identity disorder fulfilling the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-V) criteria or International Classification of Diseases 10 (ICD-10) criteria
- Reached at least Tanner stage 2 of puberty
- Gender dysphoria has emerged or worsened with the onset of puberty.
- Absence of psychiatric comorbidity that would interfere with diagnosis or treatment
- Individual will have psychological and social support during treatment.
- Demonstrated knowledge and understanding of the expected outcomes of histrelin acetate (Supprelin LA) treatment